XTalks

NOVEMBER 30, 2023

In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs).

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

XTalks

AUGUST 2, 2023

5) Lynparza (Olaparib) Lynparza is a PARP inhibitor , meaning it inhibits poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. This stops the PARP from repairing any cancer cells, causing the cells to die.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.

Life Science 111

Life Science Vaccination Vaccine Gene 111